Bristol-Myers Squibb: The TYK-2 variant inhibitor SotyKTU is better than placebo at all endpoints.

Zhitongcaijing · 09/27 15:17
Bristol-Myers Squibb: The TYK-2 variant inhibitor SotyKTU is better than placebo at all endpoints.